Revive Therapeutics | Company Profile
CSE: RVV
Latest Sector Updates
Revive is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases.
The company has a cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. It was granted FDA orphan drug designation for the use of CBD to treat liver disease as well as certain injuries resulting from organ transplants.
In February 2020 Revive Therapeutics acquired Psilocin Pharma, who have developed production solutions for the psilocybin compound and have intellectual property which covers the production of Psilocybin based formulations. Revive will advance Psilocybin based therapeutics in various diseases and disorders.
Stock information
Contact Information
Website: https://revivethera.com/
Contact Email: mfrank@revivethera.com
Corporate Presentation Link: click here
Latest Revive Therapeutics News
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
Revive Confirms No Material Undisclosed Information
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
